Does metformin improve hemodynamic and rheological responses to L-arginine in NIDDM patients?
We conclude that L-arginine infusion in newly diagnosed NIDDM patients without vascular complications produces relevant hemodynamic and theological changes, which are amplified by an 8-week treatment with metformin. Whether these vascular effects of metformin will improve the poor cardiovascular outlook of the diabetic patient is still unknown.
Sequence variation in SOD2 is not the major cause of radiotherapy complications in women with breast cancer.